IP Library › Granted Patent US 8,372,402
Granted Patent B2
US 8,372,402 · App. 13/350,641 · Granted Feb 12, 2013

Mammalian receptor proteins DCRS5; methods of treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,372,402
App. No.
13/350,641
Granted
Feb 12, 2013
Kind
B2
Abstract

Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Claims (12)

1. A method of treating a human subject experiencing an inflammatory skin disorder comprising administering an effective amount of an antagonist antibody that specifically binds to a polypeptide comprising residues 1-606 of SEQ ID NO: 2, or an antigen binding fragment thereof.

2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a monoclonal antibody or antigen binding fragment thereof.

3. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof.

4. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′) 2 fragment.

5. The method of claim 1 , wherein the skin disorder is atopic dermatitis.

6. The method of claim 5 , wherein the antibody or antigen binding fragment thereof comprises a monoclonal antibody or antigen binding fragment thereof.

7. The method of claim 5 , wherein the antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof.

8. The method of claim 5 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′) 2 fragment.

9. The method of claim 1 , wherein the skin disorder is psoriasis.

10. The method of claim 9 , wherein the antibody or antigen binding fragment thereof comprises a monoclonal antibody or antigen binding fragment thereof.

11. The method of claim 9 , wherein the antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof.

12. The method of claim 9 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′) 2 fragment.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →